AU2020405182B2 - Combination treatment of liver diseases using integrin inhibitors - Google Patents

Combination treatment of liver diseases using integrin inhibitors Download PDF

Info

Publication number
AU2020405182B2
AU2020405182B2 AU2020405182A AU2020405182A AU2020405182B2 AU 2020405182 B2 AU2020405182 B2 AU 2020405182B2 AU 2020405182 A AU2020405182 A AU 2020405182A AU 2020405182 A AU2020405182 A AU 2020405182A AU 2020405182 B2 AU2020405182 B2 AU 2020405182B2
Authority
AU
Australia
Prior art keywords
liver
compound
liver disease
fibrosis
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020405182A
Other languages
English (en)
Other versions
AU2020405182A1 (en
Inventor
Kraig Anderson
Christopher Bailey
Avirup Bose
Jacob CHA
Nicole Cooper
Darren FINKELSTEIN
Linda GREENBAUM
Johannes HULL
Susan KIRKLAND
Katerina Leftheris
Maureen REILLY
Peter TARSA
Chinweike UKOMADU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Pliant Therapeutics Inc
Original Assignee
Novartis AG
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Pliant Therapeutics Inc filed Critical Novartis AG
Publication of AU2020405182A1 publication Critical patent/AU2020405182A1/en
Application granted granted Critical
Publication of AU2020405182B2 publication Critical patent/AU2020405182B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020405182A 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors Ceased AU2020405182B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20
US62/951,615 2019-12-20
PCT/US2020/066079 WO2021127483A1 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Publications (2)

Publication Number Publication Date
AU2020405182A1 AU2020405182A1 (en) 2022-07-07
AU2020405182B2 true AU2020405182B2 (en) 2024-03-14

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020405182A Ceased AU2020405182B2 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr
WO2018051230A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Combination of fxr agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) * 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr
WO2018051230A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Combination of fxr agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Hepatol 2019 v70 pp.e57-e58 *

Also Published As

Publication number Publication date
EP4076455A1 (en) 2022-10-26
CA3165000A1 (en) 2021-06-24
JP2023507387A (ja) 2023-02-22
AU2020405182A1 (en) 2022-07-07
IL293895A (en) 2022-08-01
KR20220121838A (ko) 2022-09-01
US20230055657A1 (en) 2023-02-23
CN114929219A (zh) 2022-08-19
TW202135812A (zh) 2021-10-01
AR120859A1 (es) 2022-03-23
WO2021127483A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
RU2737324C2 (ru) Способы применения агонистов fxr
RU2743075C2 (ru) Способы применения агонистов fxr
EP4646220A1 (en) Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gain
US20220265619A1 (en) Combination treatment of liver diseases using fxr agonists
KR20170049606A (ko) 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합
AU2020408067B2 (en) Combination treatment of liver diseases using integrin inhibitors
US20210283105A1 (en) Novel regimes of fxr agonists
AU2020405182B2 (en) Combination treatment of liver diseases using integrin inhibitors
AU2020201980A1 (en) Combination of FXR agonists
KR20190062501A (ko) 섬유증, 간경화 질환 또는 질병을 치료 또는 예방하기 위한 fxr 작용제를 포함하는 조합 조성물
US20200276178A1 (en) Combinations comprising fxr agonists
JP7194745B2 (ja) チオフェン［３，２－ｄ］ピリミジン－４－ケトン系化合物の医薬用途
WO2021053618A1 (en) Treatment comprising fxr agonists
WO2025213190A1 (en) Methods of treating a disease or condition associated with weight gain
WO2025192605A1 (ja) 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired